Anti-pseudomonas Psl binding molecules and uses thereof
The disclosure relates to an anti- Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
1. A method of blocking attachment of Pseudomonas aeruginosa to epithelial cells comprising contacting a mixture of epithelial cells and P. aeruginosa with an antibody or antigen-binding fragment thereof, wherein the antibody or antibody-binding fragment thereof comprises a set of complementarity determining regions (CDRs) VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, wherein:
VHCDR1 comprises SEQ ID NO: 47,
VHCDR2 comprises SEQ ID NO: 48,
VHCDR3 comprises SEQ ID NO: 75,
VLCDR1 comprises SEQ ID NO: 50,
VLCDR2 comprises SEQ ID NO: 51, and
VLCDR3 comprises SEQ ID NO: 52.
2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is humanized, chimeric, or fully human.
3. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a Fab fragment, a Fab′ fragment, a F(ab)2 fragment or a single chain Fv (scFv).
4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is monoclonal.
5. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising SEQ ID NO: 74 and a light chain variable region (VL) comprising SEQ ID NO: 12.